Clarius Group LLC Decreases Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

Clarius Group LLC lowered its stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK) by 1.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,422 shares of the company’s stock after selling 258 shares during the quarter. Clarius Group LLC’s holdings in Scholar Rock were worth $580,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of SRRK. Mirae Asset Global Investments Co. Ltd. increased its holdings in Scholar Rock by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock worth $25,000 after purchasing an additional 514 shares during the period. GAMMA Investing LLC increased its stake in shares of Scholar Rock by 51.8% during the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock worth $34,000 after buying an additional 269 shares during the period. Quarry LP raised its holdings in Scholar Rock by 3,443.3% in the third quarter. Quarry LP now owns 4,500 shares of the company’s stock valued at $36,000 after acquiring an additional 4,373 shares in the last quarter. Hsbc Holdings PLC purchased a new position in Scholar Rock in the second quarter worth approximately $100,000. Finally, Point72 DIFC Ltd acquired a new position in Scholar Rock during the 2nd quarter worth approximately $103,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Scholar Rock news, major shareholder Public Equities L.P. Invus sold 409,433 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $38.49, for a total transaction of $15,759,076.17. Following the transaction, the insider now directly owns 10,850,005 shares of the company’s stock, valued at approximately $417,616,692.45. This trade represents a 3.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 19.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on SRRK shares. Truist Financial raised their price objective on shares of Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. BMO Capital Markets raised their price target on Scholar Rock from $34.00 to $38.00 and gave the company an “outperform” rating in a research note on Friday, October 11th. Piper Sandler upped their price objective on Scholar Rock from $28.00 to $42.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 15th. Wedbush reissued an “outperform” rating and set a $47.00 target price on shares of Scholar Rock in a research report on Thursday, January 9th. Finally, HC Wainwright boosted their target price on Scholar Rock from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $40.43.

Scholar Rock Stock Down 1.8 %

SRRK opened at $43.13 on Monday. The stock has a market capitalization of $4.04 billion, a P/E ratio of -18.35 and a beta of 0.52. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock Holding Co. has a one year low of $6.76 and a one year high of $46.19. The business’s 50-day simple moving average is $39.28 and its 200-day simple moving average is $23.08.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.